The aim of our study was to assess the dynamics of serum levels of NfL, GFAP, and tau in women exposed to adjuvant chemotherapy in early breast cancer and whether serum levels of NfL, GFAP, and tau predict and/or correlate with the severity of CIPN. This evidence concerns the gene GFAP and breast cancer.